{"filing":{"accession_number":"0001828316-26-000037","cik":"0001828316","ticker":"PHAR","company_name":"Pharming Group N.V.","form":"6-K","filing_date":"2026-09-11","report_date":"2026-09-11","primary_document":"fdaapprovespharmingsjoenja.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828316/000182831626000037/fdaapprovespharmingsjoenja.htm"},"events":[{"id":32897,"run_id":30243,"accession_number":"0001828316-26-000037","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The press release announces FDA approval of Joenja® (leniolisib) for a new pediatric indication—children aged 4 to 11 years weighing at least 27 kg with APDS. This is a material regulatory milestone that expands the drug's approved use and commercial addressable market. While not a discrete M\u0026A, financial, or governance event, it represents a significant operational and commercial achievement for a biotechnology company whose value depends on regulatory approvals and product commercialization. The approval is the first FDA-approved treatment for this pediatric APDS population, making it a material product development milestone.","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-09-11","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36186,"accession_number":"0001828316-26-000037","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces FDA approval of Joenja® (leniolisib) for a new pediatric indication—children aged 4 to 11 years weighing at least 27 kg with APDS. This is a material regulatory milestone that expands the drug's approved use and commercial addressable market. While not a discrete M\u0026A, financial, or governance event, it represents a significant operational and commercial achievement for a biotechnology company whose value depends on regulatory approvals and product commercialization. The approval is the first FDA-approved treatment for this pediatric APDS population, making it a material product development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T19:00:16.342937+00:00","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-09-11"}]}